drugset / Trial / NCT00369252
Phase I Study of Nimotuzumab in Solid Tumours
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase I trial of nimotuzumab that will be conducted in patients with advanced incurable solid tumors. This is a dose-seeking study to determine the maximum tolerated and recommended phase II doses of nimotuzumab that can be safely given to patients with advanced and/or metastatic solid tumors.
Timeline
- Start
- 2005-06
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | — | — |
Indications
No indication recorded.